Novo Nordisk rebrands as 'Novo' and introduces 'The Novo Way'

Novo Nordisk said on 14 September 2026 that it will use the single name "Novo" day-to-day, adopt the tagline "Lasting Health Starts Now," and roll out a new internal culture framework called "The Novo Way" ^[1]. The announcement came from the company's headquarters in Bagsværd, Denmark, one week before its Capital Markets Day ^[1].

The change is a branding and culture move, not a corporate restructuring. Novo Nordisk A/S remains the legal global company name, while "Novo" becomes the everyday name used with the public, partners and other stakeholders ^[1]. The visual identity keeps the Apis bull logo, which the company describes as rooted in its heritage, in what it calls a "contemporary and future-fit expression" ^[1].

What the company said

"People have always been at the centre of Novo's science. We have transformed major areas of healthcare, such as obesity and diabetes, by bringing innovation to conditions that affect millions of lives. But the unmet need remains vast, and at the same time, people's expectations of healthcare are changing," said Mike Doustdar, president and CEO ^[1]. He added that "healthcare must become more responsive, relevant and easier to fit into everyday life" and that the brand and culture work "will enhance how we operate and compete," while the company's purpose does not change ^[1].

"The Novo Way" is built around four principles: customer obsession, defined as innovating "with consumers and patients at the centre of everything we do"; competitiveness; clarity, meaning "focus and speed through clear priorities, simple ways of working and decisive action"; and care and integrity, which the company ties to respect for its people and "never compromise on patient safety and ethics" ^[1].

Tania Sabroe, executive vice president for People, Organisation and Corporate Affairs, framed the two efforts as linked: "culture shapes how we reach our strategy and how we work, while brand shapes the value that people attach to our products and services" ^[1]. The company says it has more than 67,000 employees worldwide ^[1].

The release does not announce any change to medicine brand names. Semaglutide products such as Ozempic, Wegovy and Rybelsus are not mentioned in the announcement at all, and no packaging, labeling or prescribing changes are described ^[1].

Why it matters for patients

For people taking or considering a GLP-1 medicine, the practical effect of this announcement appears limited. Nothing in the release points to changes in how drugs are named, supplied, priced or covered by insurance ^[1]. What is likely to shift over time is the look and wording of the company's advertising, websites and patient-facing materials, since the stated goal is a "distinctive, recognisable and consistent way to connect with people" and to be "more memorable and relevant to the way people engage with their health today" ^[1].

The language is worth noting for what it signals about direction. The company repeatedly uses the word "consumer" alongside "patient" and describes a market that is "faster, more competitive and increasingly consumer-driven" ^[1]. That framing matches the broader shift in obesity care toward direct-to-consumer sales and retail-style marketing, though the release itself does not spell out specific commercial plans ^[1].

It is not yet known from this announcement whether the rebrand affects US-facing patient support programs, savings offers or pharmacy channels. Those details are not in the source.

What happens next

Novo said it will give a detailed overview of its updated corporate strategy at its Capital Markets Day on 21 September in London ^[1]. That event, rather than the rebrand itself, is where any concrete commitments on pipeline, pricing or access would be expected to appear ^[1]. Separately, the company noted that a share repurchase programme begun on 6 May 2026 is continuing ^[1].